IPSC-MSCs Combined with Low-Dose Rapamycin Induced Islet Allograft Tolerance Through Suppressing Th1 and Enhancing Regulatory T-Cell Differentiation

Stem Cells and Development

Volumn 24, Issue 15, 2015, Pages 1793-1804

  Cheng, Pan Pan ^a,b   Liu, Xiao Cun ^a   Ma, Peng Fei ^c   Gao, Chang ^a   Li, Jia Li ^a   Lin, Ying Ying ^a   Shao, Wei ^d   Han, Shuo ^d   Zhao, Bin ^a   Wang, Lu Min ^a   Fu, Jia Zhao ^a   Meng, Lu Xi ^e   Li, Qing ^a   Lian, Qi Zhou ^f   Xia, Jun Jie ^a   Qi, Zhong Quan ^a  

^a XIAMEN UNIVERSITY   (China)

^b Qingdao Municipal Center for Disease Control Preventation   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d The Affiliated Chenggong Hospital of Xiamen University   (China)

^e THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CONTACT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RELEASE; LONG TERM SURVIVAL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; ANIMAL; BAGG ALBINO MOUSE; CELL DIFFERENTIATION; DOSE RESPONSE; IMMUNOLOGY; INDUCED PLURIPOTENT STEM CELL; TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

MUS;

ALLOGRAFTS; ANIMALS; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INDUCED PLURIPOTENT STEM CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED BALB C; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TRANSPLANTATION TOLERANCE;

EID: 84937721920     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0488     Document Type: Article

References (68)

1. Ruggenenti P, A Remuzzi and G Remuzzi. (2008). Decision time for pancreatic islet-cell transplantation. Lancet 371:883-884.
2. Shapiro AM, JR Lakey, EA Ryan, GS Korbutt, E Toth, GL Warnock, NM Kneteman and RV Rajotte. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238.
3. Casiraghi F, N Perico and G Remuzzi. (2013). Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant 18:51-58.
4. English K and KJ Wood. (2013). Mesenchymal stromal cells in transplantation rejection and tolerance. Cold Spring Harb Perspect Med 3:a015560.
5. Zhou HP, DH Yi, SQ Yu, GC Sun, Q Cui, HL Zhu, JC Liu, JZ Zhang and TJ Wu. (2006). Administration of donorderived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc 38:3046-3051.
6. Chabannes D, M Hill, E Merieau, J Rossignol, R Brion, JP Soulillou, I Anegon and MC Cuturi. (2007). A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110:3691-3694.
7. Popp FC, E Eggenhofer, P Renner, P Slowik, SA Lang, H Kaspar, EK Geissler, P Piso, HJ Schlitt and MH Dahlke. (2008). Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 20:55-60.
8. Casiraghi F, N Azzollini, P Cassis, B Imberti, M Morigi, D Cugini, RA Cavinato, M Todeschini, S Solini, et al. (2008). Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 181:3933-3946.
9. Ge W, J Jiang, ML Baroja, J Arp, R Zassoko, W Liu, A Bartholomew, B Garcia and H Wang. (2009). Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 9:1760-1772.
10. Eggenhofer E, P Renner, Y Soeder, FC Popp, MJ Hoogduijn, EK Geissler, HJ Schlitt and MH Dahlke. (2011). Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol 25:141-147.
11. Inoue S, FC Popp, GE Koehl, P Piso, HJ Schlitt, EK Geissler and MH Dahlke. (2006). Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 81:1589-1595.
12. Wang Y, A Zhang, Z Ye, H Xie and S Zheng. (2009). Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Transplant Proc 41:4352-4356.
13. Xu DM, XF Yu, D Zhang, MX Zhang, JF Zhou, PH Tan and YC Ding. (2012). Mesenchymal stem cells differentially mediate regulatory T cells and conventional effector T cells to protect fully allogeneic islet grafts in mice. Diabetologia 55:1091-1102.
14. Ding Y, D Xu, G Feng, A Bushell, RJ Muschel and KJ Wood. (2009). Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and-9. Diabetes 58:1797-1806.
15. Solari MG, S Srinivasan, I Boumaza, J Unadkat, G Harb, A Garcia-Ocana and M Feili-Hariri. (2009). Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun 32:116-124.
16. Li FR, XG Wang, CY Deng, H Qi, LL Ren and HX Zhou. (2010). Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells. Clin Exp Immunol 161:357-363.
17. Kim YH, YM Wee, MY Choi, DG Lim, SC Kim and DJ Han. (2011). Interleukin (IL)-10 induced by CD11b( + ) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts. Mol Med 17:697-708.
18. Ge W, J Jiang, J Arp, W Liu, B Garcia and H Wang. (2010). Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 90:1312-1320.
19. Casiraghi F, N Azzollini, M Todeschini, RA Cavinato, P Cassis, S Solini, C Rota, M Morigi, M Introna, et al. (2012). Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 12:2373-2383.
20. Kuo YR, CC Chen, HS Shih, S Goto, CW Huang, CT Wang, CL Chen and FC Wei. (2011). Prolongation of composite tissue allotransplant survival by treatment with bone marrow mesenchymal stem cells is correlated with Tcell regulation in a swine hind-limb model. Plast Reconstr Surg 127:569-579.
21. Kuo YR, CC Chen, S Goto, YT Huang, CT Wang, CC Tsai and CL Chen. (2012). Immunomodulatory effects of bone marrow-derived mesenchymal stem cells in a swine hemi-facial allotransplantation model. PLoS One 7:e35459.
22. Perico N, F Casiraghi, M Introna, E Gotti, M Todeschini, RA Cavinato, C Capelli, A Rambaldi, P Cassis, et al. (2011). Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 6:412-422.
23. Reinders ME, JW de Fijter, H Roelofs, IM Bajema, DK de Vries, AF Schaapherder, FH Claas, PP van Miert, DL Roelen, et al. (2013). Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2:107-111.
24. Riella LV and A Chandraker. (2012). Stem cell therapy in kidney transplantation. JAMA 308:130; author reply 130-131.
25. Vanikar AV and HL Trivedi. (2012). Stem cell transplantation in living donor renal transplantation for minimization of immunosuppression. Transplantation 94:845-850.
26. Peng Y, M Ke, L Xu, L Liu, X Chen, W Xia, X Li, Z Chen, J Ma, et al. (2013). Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 95:161-168.
27. Vaegler M, JK Maerz, B Amend, LA da Silva, JG Mannheim, K Fuchs, S Will, KD Sievert, A Stenzl, ML Hart and WK Aicher. (2014). Labelling and tracking of human mesenchymal stromal cells in preclinical studies and large animal models of degenerative diseases. Curr Stem Cell Res Ther 9:444-450.
28. Briquet A, S Dubois, S Bekaert, M Dolhet, Y Beguin and A Gothot. (2010). Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica 95:47-56.
29. Miura M, Y Miura, HM Padilla-Nash, AA Molinolo, B Fu, V Patel, BM Seo, W Sonoyama, JJ Zheng, CC Baker, et al. (2006). Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24:1095-1103.
30. Wagner W, P Horn, M Castoldi, A Diehlmann, S Bork, R Saffrich, V Benes, J Blake, S Pfister, V Eckstein and AD Ho. (2008). Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 3:e2213.
31. Wagner W, S Bork, P Horn, D Krunic, T Walenda, A Diehlmann, V Benes, J Blake, FX Huber, et al. (2009). Aging and replicative senescence have related effects on human stem and progenitor cells. PLoS One 4:e5846.
32. Kretlow JD, YQ Jin, W Liu, WJ Zhang, TH Hong, G Zhou, LS Baggett, AG Mikos and Y Cao. (2008). Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol 9:60.
33. Lian Q, Y Zhang, J Zhang, HK Zhang, X Wu, Y Zhang, FF Lam, S Kang, JC Xia, et al. (2010). Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 121:1113-1123.
34. Liu Y, AJ Goldberg, JE Dennis, GA Gronowicz and LT Kuhn. (2012). One-step derivation of mesenchymal stem cell (MSC)-like cells from human pluripotent stem cells on a fibrillar collagen coating. PLoS One 7:e33225.
35. Chen YS, RA Pelekanos, RL Ellis, R Horne, EJ Wolvetang and NM Fisk. (2012). Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. Stem Cells Transl Med 1:83-95.
36. Tang M, W Chen, J Liu, MD Weir, L Cheng and HH Xu. (2014). Human induced pluripotent stem cell-derived mesenchymal stem cell seeding on calcium phosphate scaffold for bone regeneration. Tissue Eng Part A 20:1295-1305.
37. Liu J, W Chen, Z Zhao and HH Xu. (2013). Reprogramming of mesenchymal stem cells derived from iPSCs seeded on biofunctionalized calcium phosphate scaffold for bone engineering. Biomaterials 34:7862-7872.
38. TheinHan W, J Liu, M Tang, W Chen, L Cheng and HH Xu. (2013). Induced pluripotent stem cell-derived mesenchymal stem cell seeding on biofunctionalized calcium phosphate cements. Bone Res 4:371-384.
39. Hynes K, D Menicanin, K Mrozik, S Gronthos and PM Bartold. (2014). Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines. Stem Cells Dev 23:1084-1096.
40. Hynes K, D Menicanin, J Han, V Marino, K Mrozik, S Gronthos and PM Bartold. (2013). Mesenchymal stem cells from iPS cells facilitate periodontal regeneration. J Dent Res 92:833-839.
41. Moslem M, MR Valojerdi, B Pournasr, A Muhammadnejad and H Baharvand. (2013). Therapeutic potential of human induced pluripotent stem cell-derived mesenchymal stem cells in mice with lethal fulminant hepatic failure. Cell Transplant 22:1785-1799.
42. Takebe T, RR Zhang, H Koike, M Kimura, E Yoshizawa, M Enomura, N Koike, K Sekine and H Taniguchi. (2014). Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant. Nat Protoc 9:396-409.
43. Sun YQ, MX Deng, J He, QX Zeng,W Wen, DS Wong, HF Tse, G Xu, Q Lian, J Shi and QL Fu. (2012). Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. Stem Cells 30:2692-2699.
44. Giuliani M, N Oudrhiri, ZM Noman, A Vernochet, S Chouaib, B Azzarone, A Durrbach and A Bennaceur-Griscelli. (2011). Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood 118:3254-3262.
45. Fu QL, YY Chow, SJ Sun, QX Zeng, HB Li, JB Shi, YQ Sun, W Wen, HF Tse, Q Lian and G Xu. (2012). Mesenchymal stem cells derived from human induced pluripotent stem cells modulate T-cell phenotypes in allergic rhinitis. Allergy 67:1215-1222.
46. Cheng PP, JJ Xia, HL Wang, JB Chen, FY Wang, Y Zhang, X Huang, QJ Zhang and ZQ Qi. (2011). Islet transplantation reverses the effects of maternal diabetes on mouse oocytes. Reproduction 141:417-424.
47. Xia J, J Chen, W Shao, T Lan, Y Wang, B Xie, H Thorlacius, F Tian, R Huang and Z Qi. (2010). Suppressing memory T cell activation induces islet allograft tolerance in alloantigen-primed mice. Transpl Int 23:1154-1163.
48. Peng Y, J Chen, W Shao, F Wang, H Dai, P Cheng, J Xia, F Wang, R Huang, Q Zhu and Z Qi. (2011). Xenoreactive CD4 + memory T cells resist inhibition by anti-CD44 mAb and reject islet grafts via a Th2-dependent pathway. Xenotransplantation 18:252-261.
49. Wang F, J Xia, J Chen, Y Peng, P Cheng, H Ekberg, X Wang and Z Qi. (2010). Combination of antibodies inhibits accelerated rejection mediated by memory T cells in xenoantigen-primed mice. Xenotransplantation 17:460-468.
50. Villa-Diaz LG, SE Brown, Y Liu, AM Ross, J Lahann, JM Parent and PH Krebsbach. (2012). Derivation of mesenchymal stem cells from human induced pluripotent stem cells cultured on synthetic substrates. Stem Cells 30:1174-1181.
51. Wei H, G Tan, Manasi, S Qiu, G Kong, P Yong, C Koh, TH Ooi, SY Lim, P Wong, SU Gan and W Shim. (2012). Onestep derivation of cardiomyocytes and mesenchymal stem cells from human pluripotent stem cells. Stem Cell Res 9:87-100.
52. Cantaluppi V, L Biancone, GM Romanazzi, F Figliolini, S Beltramo, MS Ninniri, F Galimi, R Romagnoli, A Franchello, et al. (2006). Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transplant 6:2601-2611.
53. Nishimura R, S Nishioka, I Fujisawa, H Shiku, M Shimada, S Sekiguchi, K Fujimori, A Ushiyama, T Matsue, et al. (2013). Tacrolimus inhibits the revascularization of isolated pancreatic islets. PLoS One 8:e56799.
54. Barlow AD, ML Nicholson and TP Herbert. (2013). Evidence for rapamycin toxicity in pancreatic beta-cells and a review of the underlying molecular mechanisms. Diabetes 62:2674-2682.
55. Marzorati S, R Melzi, A Citro, E Cantarelli, A Mercalli, M Scavini and L Piemonti. (2014). Engraftment versus immunosuppression: cost-benefit analysis of immunosuppression after intrahepatic murine islet transplantation. Transplantation 97:1019-1026.
56. Najar M, G Raicevic, HI Boufker, H Fayyad Kazan, C De Bruyn, N Meuleman, D Bron, M Toungouz and L Lagneaux. (2010). Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 264:171-179.
57. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
58. Sun L, K Akiyama, H Zhang, T Yamaza, Y Hou, S Zhao, T Xu, A Le and S Shi. (2009). Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27: 1421-1432.
59. Longoni B, E Szilagyi, P Quaranta, GT Paoli, S Tripodi, S Urbani, B Mazzanti, B Rossi, R Fanci, et al. (2010). Mesenchymal stem cells prevent acute rejection and prolong graft function in pancreatic islet transplantation. Diabetes Technol Ther 12:435-446.
60. Berman DM, MA Willman, D Han, G Kleiner, NM Kenyon, O Cabrera, JA Karl, RW Wiseman, DH O'Connor, AM Bartholomew and NS Kenyon. (2010). Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes 59:2558-2568.
61. Wahl SM, J Swisher, N McCartney-Francis and W Chen. (2004). TGF-beta: the perpetrator of immune suppression by regulatory T cells and suicidal T cells. J Leukoc Biol 76:15-24.
62. Read S, V Malmstrom and F Powrie. (2000). Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25( + )CD4( + ) regulatory cells that control intestinal inflammation. J Exp Med 192:295-302.
63. Green EA, L Gorelik, CM McGregor, EH Tran and RA Flavell. (2003). CD4 + CD25 + T regulatory cells control anti-islet CD8 + T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S A 100:10878-10883.
64. Abdi R, P Fiorina, CN Adra, M Atkinson and MH Sayegh. (2008). Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 57:1759-1767.
65. Yagi H, A Soto-Gutierrez, B Parekkadan, Y Kitagawa, RG Tompkins, N Kobayashi and ML Yarmush. (2010). Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 19:667-679.
66. Ribeiro A, P Laranjeira, S Mendes, I Velada, C Leite, P Andrade, F Santos, A Henriques, M Graos, et al. (2013). Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther 4:125.
67. Li X, J Bai, X Ji, R Li, Y Xuan and Y Wang. (2014). Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. Int J Mol Med 34:695-704.
68. Carrade Holt DD, JA Wood, JL Granick, NJ Walker, KC Clark and DL Borjesson. (2014). Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. Stem Cells Dev 23:1258-1265.